The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
Open accessAbstract
The human CD19 antigen is a 95 kd transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD19 is classified as a type I transmembrane protein, with a single transmembrane domain, a cytoplasmic C-terminus, and extracellular N-terminus. CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells. CD19 is critically involved in establishing intrinsic B cell signaling thresholds through modulating both B cell receptor-dependent and independent signaling. CD19 functions as the dominant signaling component of a multimolecular complex on the surface of mature B cells, alongside complement receptor CD21, and the tetraspanin membrane protein CD81 (TAPA-1), as well as CD225. Through study of CD19 transgenic and knockout mouse models, it becomes clear that CD19 plays a critical role in maintaining the balance between humoral, antigen-induced response and tolerance induction. This review also summarized latest clinical development of CD19 antibodies, anti-B4-bR (an immunotoxin conjugate), blinatumomab (BiTE), and SAR3419 (huB4-DM4), a novel antibody-drug conjugate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy
Pruitt, K. D., Tatusova, T., Brown, G. R., & Maglott, D. R. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr1079 · Cited by 1,149 · cited 1×
“There are more than one mRNA transcripts, though only two transcript isoforms have been isolated in vivo [5-7].”
BackgroundCD19: Lowering the Threshold for Antigen Receptor Stimulation of B Lymphocytes
Carter, R. H., & Fearon, D. T. (1992) · Science · doi:10.1126/science.1373518 · Cited by 674
Impairment of T-cell-dependent B-cell responses and B-l cell development in CD19-deficient mice
Rickert, R. C., Rajewsky, K., & Roes, J. (1995) · Nature · doi:10.1038/376352a0 · Cited by 664
AceView: a comprehensive cDNA-supported gene and transcripts annotation
Thierry-Mieg, D., & Thierry-Mieg, J. (2006) · Genome Biology · doi:10.1186/gb-2006-7-s1-s12 · Cited by 629
Engel, P., Zhou, L.-J., Ord, D. C., Sato, S., Koller, B., & Tedder, T. F. (1995) · Immunity · doi:10.1016/1074-7613(95)90157-4 · Cited by 541
An Antibody-Deficiency Syndrome Due to Mutations in the CD19 Gene
van Zelm, M. C., Reisli, I., van der Burg, M., Castaño, D., van Noesel, C. J. M., van Tol, M. J. D., Woellner, C., Grimbacher, B., Patiño, P. J., van Dongen, J. J. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051568 · Cited by 540
Bradbury, L. E., Kansas, G. S., Levy, S., Evans, R. L., & Tedder, T. F. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.9.2841 · Cited by 402
Tedder, T. F., Inaoki, M., & Sato, S. (1997) · Immunity · doi:10.1016/s1074-7613(00)80418-5 · Cited by 383
Cited by
Immune function and micronutrient requirements change over the life course
Maggini, S., Pierre, A., & Calder, P. C. (2018) · Nutrients · doi:10.3390/nu10101531 · Cited by 710
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Caimi, P. F., Ai, W., Alderuccio, J. P., Ardeshna, K. M., Hamadani, M., Hess, B., Kahl, B. S., Radford, J., Solh, M., Stathis, A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00139-x · Cited by 441
Thompson, J. A., Schneider, B. J., Brahmer, J., Achufusi, A., Armand, P., Berkenstock, M. K., Bhatia, S., Budde, L. E., Chokshi, S., Davies, M., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0020 · Cited by 426
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
Metadata
- Authors
- Wang, K., Wei, G., & Liu, D.
- Venue
- Experimental Hematology & Oncology
- Published
- 2012-11-29
- Volume
- 1
- Issue
- 1
- Pages
- 36-36
- ISSN
- 2162-3619 (ISSN-L)
- OpenAlex
- W2136453261
- Cited by
- 562
- References
- 35
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. https://app.cochat.ai/papers/10.1186/2162-3619-1-36
- The paper
- Wang, K., Wei, G., & Liu, D. (2012). CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Experimental Hematology & Oncology. https://doi.org/10.1186/2162-3619-1-36
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.